Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration is correcting a notice entitled "Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal" that appeared in the Federal Register of December 13, 2022. The document announced the renewal of the Cardiovascular and Renal Drugs Advisory Committee. The document was published with the incorrect docket number. This document corrects that error.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 7 (Wednesday, January 11, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 7 (Wednesday, January 11, 2023)]
[Notices]
[Pages 1599-1600]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-00390]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-3091]
Advisory Committee; Cardiovascular and Renal Drugs Advisory
Committee; Renewal; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is correcting a notice
entitled ``Advisory Committee; Cardiovascular and Renal Drugs Advisory
Committee; Renewal'' that appeared in the Federal Register of December
13, 2022. The document announced the renewal of the
[[Page 1600]]
Cardiovascular and Renal Drugs Advisory Committee. The document was
published with the incorrect docket number. This document corrects that
error.
FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy,
Planning, Legislation and International Affairs, Food and Drug
Administration, 301-796-9115, <a href="/cdn-cgi/l/email-protection#98d4f1ebf9b6dfeaf9f6fffdead8fefcf9b6f0f0ebb6fff7ee"><span class="__cf_email__" data-cfemail="a0ecc9d3c18ee7d2c1cec7c5d2e0c6c4c18ec8c8d38ec7cfd6">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In the Federal Register of Tuesday, December
13, 2022 (87 FR 76197), in FR Doc. 2022-27014, on page 76197 the
following correction is made:
1. On page 76197, in the first column of the header of the
document, ``Docket No. FDA-2022-N-3091'' is corrected to read ``Docket
No. FDA-2018-N-3091''.
Dated: January 3, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-00390 Filed 1-10-23; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.